Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorOzaslan, Ersin
dc.contributor.authorTopaloglu, Ulas Serkan
dc.contributor.authorInanc, Mevlude
dc.contributor.authorErdem, Umut Gokmen
dc.contributor.authorDemir, Hacer
dc.contributor.authorArpaci, Erkan
dc.contributor.authorSeker, Mehmet Metin
dc.contributor.authorKaraaga, Mustafa
dc.contributor.authorKiziltepe, Melih
dc.contributor.authorEker, Baki
dc.contributor.authorOzkan, Metin
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:40:50Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:40:50Z
dc.date.issued2017
dc.department[Ozaslan, Ersin -- Inanc, Mevlude] Kayseri Training & Res Hosp, Dept Med Oncol, Kayseri, Turkey -- [Ozaslan, Ersin -- Inanc, Mevlude -- Ozkan, Metin] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey -- [Topaloglu, Ulas Serkan -- Kiziltepe, Melih -- Eker, Baki] Kayseri Training & Res Hosp, Dept Internal Med, TR-38010 Kayseri, Turkey -- [Topaloglu, Ulas Serkan -- Kiziltepe, Melih] Erciyes Univ, Dept Internal Med, Fac Med, Kayseri, Turkey -- [Erdem, Umut Gokmen] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Demir, Hacer] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey -- [Arpaci, Erkan] Bulent Ecevit Univ, Fac Med, Dept Med Oncol, Zonguldak, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Karaaga, Mustafa] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkeyen_US
dc.description.abstractPurpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were also given irinotecan and/or oxaliplatin combined with fluoropyrimidine +/- bevacizumab. Tumor response and survival were evaluated using RECIST and Kaplan-Meier method respectively. Results: Sixty patients were included this study. Cetuximab plus FOLFOX was administered to 40 (66.7%) patients as second-line and to 20 (33.3%) as third-line therapy. Themajority of the patients had a good ECOG performance status (PS) (0 or 1). Clinical benefit was partial plus stable disease and it was 75.0% for both of these two lines. The median progression free survival (PFS) was 7.1 months (95% CI=3.2-10.9) and 6.0 months (95% CI=2.4-9.6), in the second- and third-line (p=0.484). The median overall survival (OS) was 14.3 and 9.2 months in second- and third-line therapy respectively (p=0.071). The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2. Conclusion: The addition of cetuximab to FOLFOX was well-tolerated and had antitumor activity both in second and third-line therapy in patients with mCRC.en_US
dc.identifier.endpage868en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid29155512en_US
dc.identifier.scopus2-s2.0-85045577395en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage863en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12418/6730
dc.identifier.volume22en_US
dc.identifier.wosWOS:000412789500007en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIMPRIMATUR PUBLICATIONSen_US
dc.relation.ispartofJOURNAL OF BUONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcetuximaben_US
dc.subjectchemotherapyen_US
dc.subjectcolorectal canceren_US
dc.subjectsecond lineen_US
dc.subjectthird lineen_US
dc.titleEfficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu